Temprian Therapeutics

Biotechnology

Overview

Temprian Therapeutics is an early-stage biotechnology company treating vitiligo through a novel treatment that blocks the autoimmune response to melanocytes.

Funding and backers

Total raised
$275k
1 round on record
Latest round
$275k
Convertible Note · Jan 2019 · 7 yr ago
Team
51-200
employees, estimated range
The money's age
Long since its last round
93 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jan 25, 2019 Raised a round Convertible Note $275k · SEC Form D 2019 Founded
Funding rounds
RoundDateAmountInvestorsSource
Convertible Note Jan 2019 $275k — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity TEMPRIAN THERAPEUTICS, INC. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Kettil CedercreutzExecutive Officer, DirectorSEC Form D
Isabelle Le PooleExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Broadview Ventures
backs Biokier, Lyra Therapeutics
SOSV
backs Reach Neuro
RA Capital Management
backs Lyra Therapeutics
Similar startupsby what they do, their industry and backers
Epitome Therapeutics FlexCoFounded 2025
Epitome Therapeutics is an early-stage biotechnology company, focused on developing a next-generation epigenome editing platform to…
Reach NeuroConvertible Note $200k · 4 yr ago · Founded 2021
We are an early stage startup developing the first-ever treatment for chronic disability caused by stroke.
PraeventixVenture round $5.6M · 9 mo ago · Founded 2022 · 51-200 employees
About About Praeventix Praeventix is an early-stage biotech company committed to the discovery, research and early clinical development of…
Startup VesselVenture round $75M · 12 yr ago
Startup Vessel is a startup software directory for founder workflows, early-stage operations, and startup execution.
Life AdaptVenture round $700 · 2 yr ago · Founded 2023
Innovationand Impact. As an early-stage startup, we are looking to make a significant impact.
Biokier11-50 employees
About Us BioKier Inc. is an early-stage pharmaceutical company developing new proprietary medical foods and drugs for diabetes and related…

Financials

Total raised
$275k
Latest round
Convertible Note
Funding rounds
1
Funding rounds
Round Announced Amount
Convertible Note 2019 $275k Details

People

Kettil Cedercreutz
Executive Officer, Director
SEC Form D
Isabelle Le Poole
Executive Officer, Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Chicago United States
HQ
50-200 est. staff